Companies / Balchem COMPANY FILINGS
Balchem BCPC In fiscal 2025, Balchem developed, manufactured and marketed specialty ingredients and products for nutrition, food, pharmaceutical, animal health, plant nutrition, sterilization, fumigation and industrial markets. Its reportable segments were Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.
Business description: FY2025 CIK 0000009326 Source: SEC EDGAR
Overview 10-K summary Balance sheet Original filings
Annual reports 5
Report coverage 2021–2025
Financial statement focus Balance sheet READ THE FILING
Annual report insights AI summary AI-generated summaries of the cited 10-K filings. For informational purposes only; not personalized investment advice.
Choose a fiscal year FY2025 Balchem reported consolidated net sales growth of 8.8% and net earnings growth of 20.5% in fiscal 2025 compared with fiscal 2024.
Source: 2025 On December 19, 2025, the European Commission published definitive duties of 90.0% to 115.9% on Chinese-origin choline chloride imports into the European Union. Choline chloride is a nutrient used in animal feed. The investigation followed a complaint by Balchem Italia and another complainant.
Source: 2025 View full 10-K summary 2025 Hide full 10-K summary 2025 Signals describe observations in the selected filing, not forecasts or investment ratings. Risk disclosures do not establish that a loss occurred.
Positive signals Operating cash Cash provided by operating activities was US$216.556 million in 2025, compared with US$181.999 million in 2024, a reported increase of 19.0%. Management attributed the increase primarily to higher net earnings and changes in working capital—the short-term operating assets and liabilities involved in day-to-day business.
Source: 2025 Negative signals EtO restrictions The U.S. Environmental Protection Agency's (EPA) decision on ethylene oxide, a chemical used for sterilization, contemplated annual worker-exposure data from users, including Balchem's customers. Companies holding the product registrations may not continue selling ethylene oxide to customers that fail to provide those data. Balchem warned that, if the decision and other requirements remain unchanged, they would likely increase costs and regulatory burdens.
Source: 2025 BCP settlement BCP Ingredients, Inc., Balchem's subsidiary operating its Verona, Missouri site, entered a settlement with the U.S. Environmental Protection Agency (EPA) and U.S. Department of Justice (DOJ) on January 31, 2025 to resolve alleged violations. It agreed to pay a civil penalty, invest in a new pollution-control scrubber system and fund projects benefiting the surrounding community. The filing described alleged violations and the settlement obligations.
Source: 2025 Business context EtO decision In January 2025, the U.S. Environmental Protection Agency (EPA) re-registered ethylene oxide for medical-device sterilization and microbial reduction on certain spices and seasonings. The decision provided for a phase-out on certain spices and discontinued minor applications, including musical instruments, cosmetics and archival materials. It remained subject to further review and stakeholder input.
Source: 2025 Business in fiscal 2025 In fiscal 2025, Balchem developed, manufactured and marketed specialty ingredients and products for nutrition, food, pharmaceutical, animal health, plant nutrition, sterilization, fumigation and industrial markets. Its reportable segments were Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.
Source: 2025
5-year changes FY2021–FY2025 These changes use selected original filing passages and nearby context from the stated five fiscal years. They are not an exhaustive review of all five reports and exclude later-year filings.
Segment sales Human Nutrition and Health net sales increased from US$442.733 million in 2021 to US$659.387 million in 2025. Animal Nutrition and Health followed a different path: sales were US$262.297 million in 2022, fell to US$214.710 million in 2024, and recovered to US$230.852 million in 2025, still below 2022. These are reported segment figures, not growth adjusted to exclude acquisitions.
Source: 2021 , 2022 , 2024 , 2025 Borrowing costs Balchem funded its 2022 Kappa and Bergstrom acquisitions through credit agreements. Management attributed the subsequent increase in 2023 interest expense to acquisition-related borrowings and higher interest rates. In both 2024 and 2025, management instead attributed declining net interest expense mainly to lower outstanding borrowings. These explanations describe the individual annual changes, not a single cause for the entire five-year period.
Source: 2022 , 2023 , 2024 , 2025 EtO regulation The 2023 report described proposed EPA emissions rules for ethylene oxide sterilization facilities that had not yet been finalized; the 2025 report described those rules as implemented. Separately, the January 2025 registration decision retained medical-device sterilization uses while providing for a phase-out on certain spices and discontinuing minor applications. Future effects remained conditional: Balchem warned that additional regulation could require users to suspend operations temporarily or limit ethylene oxide use.
Source: 2023 , 2025 Request a correction FINANCIAL STATEMENTS
Balance sheet A snapshot of what Balchem owns and owes at a point in time.
The original comes first. Read the company’s balance sheet in the original annual reports below.
Browse original filings
Assets What the company owns
Liabilities What the company owes
Equity Assets less liabilities See the original statement for its reporting period, currency, and unit.
SOURCE LIBRARY
Annual reports & SEC 10-K filings SEC EDGAR 5 reports in this collection
Report yearAll years 2025 2024 2023 2022 2021 Dates describe the filing metadata. Figures and reporting periods should be checked against the original statement. SEC links open in a new tab.
About this collection This is a selected archive of up to ten annual reports per company. It does not include every filing or update automatically. Visit the original SEC filings for the full context.
Our approach to the data 